What Shifamed does

Shifamed, LLC is a privately held medical technology innovation hub founded in 2007 by serial medical device entrepreneur Amr Salahieh, operating from a nine-building campus in Campbell, California. The company functions as a venture-backed incubator that identifies, develops, and spins out portfolio companies focused on cardiovascular, ophthalmology, and medical device enterprise software. Its current portfolio of eight operating companies includes Adona Medical (adjustable interatrial shunt with bi-atrial pressure monitoring), Akura Medical (Katana Thrombectomy System with NavIQ CT-based quantification software), Atia Vision (modular presbyopia-correcting OmniVu intraocular lens), Laza Medical (AI-powered robotic cardiac imaging with real-time 3D heart modeling), Myra Vision (Calibreye titratable glaucoma therapy), Supira Medical (next-generation 10F percutaneous ventricular assist device), Tioga Cardiovascular (Luna transcatheter mitral valve replacement system), and Enlil (LLM-enabled MedTech development traceability platform).

Shifamed provides centralized shared infrastructure including R&D, engineering, prototyping, clinical development, regulatory affairs, intellectual property, finance, and human resources to its portfolio companies, which operate as independent Delaware entities with dedicated CEOs. The leadership team — including Amr Salahieh (Founder & CEO), Mariam Maghribi (Chief Business Officer and CEO of Atia Vision and Tioga), David Voris (CFO across all portfolio companies), Debbie White (Chief People Officer), and Robert Edesess (VP, IP) — has a documented track record of six prior exits: Embolic Protection Inc. ($75M to Boston Scientific, 2001), Sadra Medical ($225M + $225M milestones to Boston Scientific, 2011), Maya Medical ($60M + $170M milestones to Covidien, 2012), Kalila Medical (undisclosed to Abbott, 2016), Apama Medical ($175M + $125M milestones to Boston Scientific, 2017), and NuVera Medical (undisclosed to J&J, 2020).

The business model is venture-capital-style returns through strategic acquisitions of portfolio companies, supplemented by capital raises from institutional and strategic investors (Cormorant Asset Management, The Capital Partnership, Novo Holdings, Qatar Investment Authority, GE HealthCare). Shifamed and its management team have raised over $800M to date across portfolio companies. Pricing is not applicable because none of the eight current portfolio companies has reached commercialization; multiple FDA Breakthrough and IDE approvals have been secured in 2023-2026, positioning several products for pivotal trials and eventual U.S. market entry. Customers in the clinical trial phase include interventional cardiologists, ophthalmologists, and glaucoma specialists at major U.S. academic medical centers (Duke, Columbia/NewYork-Presbyterian, Piedmont Heart Institute, Oregon Health Sciences University, Moorfields Eye Hospital).

Name

Shifamed

Legal name

Shifamed, LLC

Website

https://shifamed.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

Shifamed is a private medical technology innovation hub founded in 2007 by Amr Salahieh, operating a nine-building Silicon Valley campus that incubates eight cardiovascular, ophthalmology, and MedTech software portfolio companies, having raised over $800M and produced six prior exits to Boston Scientific, Covidien, Abbott, and Johnson & Johnson.

Ownership category

akta.pro rank

Product category

Medical Devices (cardiovascular, ophthalmology, and MedTech software)

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

Keywords

• Medical device innovation
• Medical technology incubator
• Cardiovascular medical devices
• Ophthalmic medical devices
• MedTech venture studio

Headquarters

HQ city

Campbell

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Portfolio Company Exits: Shifamed generates returns through successful exits of portfolio companies via acquisition by strategic buyers. Legacy portfolio includes companies sold to Boston Scientific, Covidien, Abbott, and Johnson & Johnson.
2. Internal Company Development: Shifamed and its dedicated management team have raised over $800M to date for its portfolio companies through venture capital, strategic investors, and institutional investors.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Shifamed is a medical technology innovation hub that conceives, develops, and operates wholly owned portfolio companies building next-generation medical devices and software in cardiovascular, ophthalmology, and MedTech compliance. It provides centralized R&D, engineering, prototyping, clinical development, regulatory, and manufacturing infrastructure from a nine-building Silicon Valley campus, raising over $800M for portfolio companies and harvesting returns through strategic acquisitions by major medical device firms.

Product overview

Shifamed operates as a medical technology innovation hub with a portfolio of eight distinct portfolio companies, each developing specialized medical devices across cardiovascular, ophthalmology, and enterprise software domains. The portfolio includes: Myra Vision's Calibreye adjustable glaucoma shunt; Akura Medical's Katana Thrombectomy System and NavIQ quantification software for VTE care; Atia Vision's OmniVu modular intraocular lens; Supira Medical's low-profile pVAD; Tioga Cardiovascular's Luna TMVR system; Laza Medical's AI-powered robotic cardiac imaging; Enlil's AI-powered traceability platform for MedTech compliance; and Adona Medical's adjustable interatrial shunt with hemodynamic monitoring. These companies operate as independent entities with dedicated leadership while sharing Shifamed's infrastructure and resources.

Differentiator

Problem solved

Functional benefit

Products and services

• Myra Vision Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System Adjustable aqueous shunt for glaucoma patients enabling clinician-directed postoperative outflow adjustments via slit lamp-based titration, providing personalized intraocular pressure management for moderate to severe glaucoma.
• Akura Medical Katana™ Thrombectomy System Intelligent thrombectomy system with high-velocity saline jets designed to remove diverse clot types in venous thromboembolism, featuring sensors for real-time pulmonary artery pressure monitoring and a Sentinel Console displaying clot engagement and blood loss.
• NavIQ™ Quantification Software Software that converts CT angiograms into 3D models of pulmonary vasculature for pre-procedural planning, providing anatomical visualization and automated clot characterization data for physicians planning thrombectomy procedures.
• Atia Vision OmniVu™ Lens System Modular presbyopia-correcting intraocular lens with a fluid-filled shape-changing base and fixed-power front optic designed to restore dynamic range of vision following cataract surgery by harnessing the eye's natural accommodative mechanism.
• Supira Medical Percutaneous Ventricular Assist Device (pVAD) Next-generation low-profile (10F) high continuous flow pVAD designed to provide full hemodynamic support for high-risk percutaneous coronary interventions and cardiogenic shock, with multiple sensors for real-time pressure monitoring.
• Tioga Cardiovascular Luna™ Transcatheter Mitral Valve Replacement (TMVR) System Transcatheter mitral valve replacement system designed for transseptal delivery with a 28 French profile, focused on procedurally simpler and less invasive mitral valve replacement.
• Laza Medical AI-Powered Robotic Imaging Solution AI-powered robotic imaging solution combining real-time AI heart models constructed from ultrasound data with robotically assisted transesophageal echocardiography (TEE) control to address complexity and resource burden in image-guided cardiac interventions.
• Enlil Development Traceability Platform Cloud-native enterprise software platform integrating AI-powered tools including a private LLM-driven chatbot to help MedTech companies streamline product development, compliance, and regulatory processes.
• Adona Medical Interatrial Shunt with Bi-Atrial Pressure Monitoring Adjustable interatrial shunt with integrated sensors designed to capture pressure readings from both left and right atria multiple times per day, featuring adjustable flow channel geometry that can be modified post-implantation via proprietary induction catheter for heart failure management.

Quantifiable outcome

• Over 350 employees across campus and 50+ OUS employees
• +2 more outcomes

Named customers12 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature2 records

Partnerships

17 partnerships are on record, tiered key and core.

• Dr. Ajay Kirtane (Columbia University)keyImplementation/ SI/ Consulting Partner · 8 April 2026National co-principal investigator for Supira Medical's SUPPORT II Pivotal Trial and Professor of Medicine at Columbia University/NewYork-Presbyterian Hospital.
• Dr. David Kandzari (Piedmont Heart Institute)keyImplementation/ SI/ Consulting Partner · 8 April 2026National co-principal investigator and Chief Scientific Officer for Piedmont Healthcare, leading Supira Medical's SUPPORT II pivotal trial.
• D. Keith GrossmankeyOthers · 8 April 2026Appointed to Supira Medical's Board of Directors in April 2026. 40-year medical device industry veteran with foundational experience in mechanical circulatory support space.
• Amr SalahiehcoreOthersFounder and CEO of Shifamed, with over 30 years of healthcare experience and inventor/co-inventor on over 400 patent applications worldwide. Previously led multiple successful exits including Embolic Protection Inc., Sadra Medical, Maya Medical, Kalila Medical, Apama Medical, and NuVera Medical.
• Mariam MaghribicoreOthersChief Business Officer of Shifamed, CEO of Atia Vision and Tioga Cardiovascular. 21 issued US patents, holds B.S. from Georgia Tech, Ph.D. in Biomedical Engineering from UC Davis, and dual M.B.A. degrees from Columbia Business School and UC Berkeley Haas.
• David VoriscoreOthersChief Financial Officer of Shifamed with over 25 years of experience in financial and operating executive leadership for early-stage and mid-sized medical device companies. Certified public accountant with experience at Deloitte, Optovue, and Laser Diagnostic Technologies.
• Debbie WhitecoreOthersChief People Officer for Shifamed and its portfolio companies with over 25 years of experience in medical device industry. Recognized as human resources and administrative start-up expert with multiple IPO and acquisition experience.
• Robert EdesesscoreOthersVP, Intellectual Property with over 15 years of experience advising life sciences companies. Previously Assistant General Counsel IP for Thoratec prior to its $3.4B acquisition by St. Jude Medical and subsequent $25B acquisition by Abbott.
• Nader FathicoreOthersCEO of Enlil appointed in February, leading the company's development traceability platform serving over 600 MedTech users worldwide.
• Pablo GarciacoreOthersGeneral Manager of Laza Medical appointed in December 2023. Previously VP of Digital Solutions for Johnson & Johnson and technical co-founder of Verb Surgical (acquired by J&J). Brings over two decades of medical device development and leadership experience.
• Robert ChangcoreOthersPresident and CEO of Myra Vision leading the Calibreye TGT Surgical System development and ADAPT clinical study.
• Murali SrivathsacoreOthersPresident and CEO of Akura Medical leading development of the Katana Thrombectomy System and NavIQ quantification software.
• Dr. Nitin SalunkecoreOthersPresident and CEO of Supira Medical leading development of the pVAD system. Successfully advanced clinical programs through feasibility studies and pivotal trial preparation.
• Mike DineencoreOthersPresident and CEO of Tioga Cardiovascular leading development of the Luna TMVR system through first-in-human cases.
• Brian FaheycoreOthersCo-Founder and CEO of Adona Medical leading development of adjustable interatrial shunt with integrated bi-atrial pressure monitoring.
• Dr. David Godfrey (Glaucoma Associates of Texas)keyImplementation/ SI/ Consulting PartnerClinical investigator who performed the first patient treatment in Myra Vision's ADAPT clinical study at Glaucoma Associates of Texas.
• Dr. Samuel Horr (TriStar Centennial Medical Center)keyImplementation/ SI/ Consulting PartnerDirector of Cardiovascular Research at TriStar Centennial who performed the first patient enrollment in Akura Medical's QUADRA-PE pivotal trial.

Scale indicators6 records

Recent moves6 records

Expansion highlights3 records

Broad incumbents

• Stryker's Instruments Division: Large incumbent medical device company with M&A and internal incubation history targeting cardiology, surgical, and orthopedic specialties. Comparable to Shifamed as a strategic acquirer for medtech assets and as a model of integrated device innovation, though operating at much larger scale.
• Edwards Lifesciences: Global leader in structural heart disease therapies (TAVR, surgical heart valves) and critical care monitoring. Directly comparable to Tioga Cardiovascular's TMVR focus and Supira's hemodynamic monitoring, and represents a likely strategic acquirer for Shifamed portfolio companies in the structural heart space.
• Boston Scientific: Major medical device incumbent that has acquired three Shifamed portfolio companies (Embolic Protection, Sadra Medical, Apama Medical). Comparable to Shifamed as a structural-heart and interventional-cardiology device-maker and as the most frequent strategic acquirer of Shifamed-created companies.
• JLABS (Johnson & Johnson Innovation): Johnson & Johnson's global life sciences incubator network providing infrastructure, mentoring, and capital to early-stage medical device and biotech companies. Comparable to Shifamed at the portfolio-infrastructure level, though JLABS operates as a strategic's external innovation arm rather than an independent serial entrepreneur hub.

Direct peers

• Coridea: Medical device incubator co-founded by serial medtech entrepreneurs that operates as a founder-friendly collaboration platform to develop and spin out cardiovascular and other therapeutic device companies. Closely comparable to Shifamed's incubation model with multiple successful exits to strategics.
• ExploraMed: Medical device incubator founded by Dr. Josh Makower focused on developing and commercializing minimally invasive medical devices through created companies. Comparable to Shifamed through its model of multi-portfolio medtech innovation with strategic exit orientation.
• InCube Labs: Multi-disciplinary life sciences incubator founded by Mir Imran that develops and commercializes medical devices through portfolio companies. Comparable to Shifamed in being a serial entrepreneur-driven incubator focused on bringing breakthrough medical devices from ideation to commercialization.
• The Foundry: Silicon Valley medical device incubator founded by serial medtech entrepreneurs that creates, incubates, and spins out companies addressing unmet clinical needs. Directly comparable to Shifamed's hub model of seeding and scaling medical device companies through centralized R&D and successful exit to strategics.

Emerging players

• Inspire Medical Systems: Recently commercialized medtech company that scaled a single breakthrough device (hypoglossal nerve stimulation for sleep apnea) from startup to public company. Comparable to Shifamed's portfolio companies as a model of how a single medtech asset can grow into a category-defining commercial franchise.

Others

• Polaris Partners: Venture capital firm with significant medical device practice that creates and funds medtech startups. Comparable to Shifamed's investor and capital-nurture role across portfolio companies, though operating as a financial sponsor rather than an operating innovation hub.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/shifamed
• YouTubeyoutube.com/shifamed
• Xx.com/shifamed

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shifamed